Cargando…

Selectively high efficacy of eribulin against high-grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have a poor prognosis. Over the past decade, a major development in the first-line treatment of R/M SCCHN was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Yutaka, Kitahara, Hiroko, Hirai, Mariko, Tanaka, Akira, Jokaji, Rei, Kobayashi, Kazuhiko, Bou-Gharios, George, Nakamura, Hiroyuki, Kawashiri, Shuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507455/ https://www.ncbi.nlm.nih.gov/pubmed/31186718 http://dx.doi.org/10.3892/ol.2019.10165

Ejemplares similares

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment
por: Hirai, Mariko, et al.
Publicado: (2016)

Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition
por: Kitahara, Hiroko, et al.
Publicado: (2016)

Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage
por: Hira-Miyazawa, Mayuko, et al.
Publicado: (2017)

Metalloelastase-12 is involved in the temporomandibular joint inflammatory response as well as cartilage degradation by aggrecanases in STR/Ort mice
por: Yamashita-Futani, Yoko, et al.
Publicado: (2021)

Elastin-derived peptides are involved in the processes of human temporomandibular disorder by inducing inflammatory responses in synovial cells
por: Kobayashi, Kazuhiko, et al.
Publicado: (2017)

Clinicopathological Significance of the ET Axis in Human Oral Squamous Cell Carcinoma
por: Miyazawa, Hiroki, et al.
Publicado: (2018)

Evaluation of factors related to morphological masseter muscle changes after preoperative orthodontic treatment in female patients with skeletal class III dentofacial deformities
por: Jokaji, Rei, et al.
Publicado: (2022)

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
por: Kawai, Akira, et al.
Publicado: (2022)

Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition
por: KIMURA, IYO, et al.
Publicado: (2016)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Eribulin shows high concentration and long retention in xenograft tumor tissues
por: Sugawara, Michiko, et al.
Publicado: (2017)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models
por: Ho, Gwo Yaw, et al.
Publicado: (2023)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

Aggrecanase-selective tissue inhibitor of metalloproteinase-3 (TIMP3) protects articular cartilage in a surgical mouse model of osteoarthritis
por: Nakamura, Hiroyuki, et al.
Publicado: (2020)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
por: Iwasa, Tsutomu, et al.
Publicado: (2019)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Eribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study
por: Murakami, Manabu, et al.
Publicado: (2019)

Regression of brain metastases from breast cancer with eribulin: a case report
por: Matsuoka, Hiromichi, et al.
Publicado: (2013)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

Development of interstitial pneumonia during treatment with eribulin: a case report
por: Nakamura, Kota, et al.
Publicado: (2017)

Primary T-cell high-grade lymphoma of the feline uterus
por: AZAKAMI, Daigo, et al.
Publicado: (2016)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

An α-chloroaldehyde-based formal synthesis of eribulin
por: Kaghad, Anissa, et al.
Publicado: (2023)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Molecular profiles of high‐grade and low‐grade pseudomyxoma peritonei
por: Noguchi, Rei, et al.
Publicado: (2015)

Changes in Crystal Structure and Accelerated Hydrolytic Degradation of Polylactic Acid in High Humidity
por: Kobayashi, Yutaka, et al.
Publicado: (2021)

Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study
por: Kobayashi, Takayuki, et al.
Publicado: (2016)

High doses of TGF-β potently suppress type I collagen via the transcription factor CUX1
por: Fragiadaki, Maria, et al.
Publicado: (2011)

Eribulin for Advanced Breast Cancer: A Drug Evaluation
por: Shablak, Alaaeldin
Publicado: (2013)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

In vitro radiosensitization by eribulin in human cancer cell lines
por: Benlloch, Raquel, et al.
Publicado: (2022)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
por: López-Álvarez, María, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b7d8c28r1jll48p5bj6saks1vg